HIGHLIGHTS
- who: Marco Salvetti and Giovanni Ristori from the Research Network, Iran University of Siena, Italy have published the article: Intestinal Permeability and Circulating CD161+CCR6+CD8+T Cells in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Dimethylfumarate, in the Journal: (JOURNAL)
- what: The study was conducted after approval of the local Ethics Committee, and a signed informed consent was obtained from each patient. The authors investigated IP changes, the circulating CD161+CD8+ T-cell subset, and clinical/neuroradiological data in a cohort of RRMS patients before and after 9 months of DMF therapy, with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.